Delivra Health Issues News Release Amendment Regarding Proposed Shares for Debt Transaction

Delivra Health corrects its shares-for-debt settlement to 999,999 shares for $90,000 payables.

What the company is saying

Delivra Health Brands Inc. is issuing a correction to its November 11, 2026 announcement regarding a shares-for-payables settlement. The company clarifies that it will issue 999,999 common shares at a deemed price of $0.09 per share, settling approximately $90,000 in outstanding payables for services provided. This replaces the previously reported figure of 9,999,999 shares, which was a typographical error. The company emphasizes that all other terms of the prior release remain unchanged. The transaction is subject to TSX Venture Exchange approval. The tone is factual and procedural, focusing on correcting the record and providing precise figures for the transaction. No executives are named, and no forward-looking claims beyond the completion of this settlement are made.

What the data suggests

The company will settle $90,000 in payables by issuing 999,999 shares at $0.09 each, pending TSX Venture Exchange approval. The correction reduces the dilution from the previously misstated 9,999,999 shares to the accurate 999,999 shares. After the transaction, the total shares outstanding will be 32,261,780 on a non-diluted basis. The figures are internally consistent, with $0.09 per share matching the $90,000 aggregate settlement. No additional financial, operational, or strategic information is disclosed. The announcement is narrowly focused on correcting the share count and clarifying the company's capital structure post-transaction.

Analysis

The announcement is a factual correction regarding the number of shares to be issued in a shares-for-payables settlement. The language is strictly procedural, with no promotional or exaggerated claims about future benefits or company prospects. The only forward-looking elements are the completion of the settlement and the requirement for TSX Venture Exchange approval, both of which are standard and not hyped. There is no discussion of operational growth, profitability, or strategic impact, and no attempt to frame the transaction as transformative or value-creating. The capital outlay is modest ($90,000 in payables), and the transaction is routine for a small-cap issuer. The gap between narrative and evidence is nonexistent; the disclosure is proportionate and corrective.

Risk flags

• ●The transaction is subject to TSX Venture Exchange approval, introducing a procedural risk that could delay or alter the settlement if approval is not granted as expected.
• ●Issuing shares to settle payables, even at a modest scale, results in dilution for existing shareholders, which can impact per-share value and future capital-raising flexibility.
• ●The announcement provides no broader financial or operational context, limiting investor visibility into the company's overall financial health and liquidity beyond this specific transaction.

Bottom line

This correction clarifies that Delivra Health will issue 999,999 shares at $0.09 each to settle $90,000 in payables, not the tenfold higher figure previously reported. The transaction is routine and only modestly dilutive, with post-settlement shares outstanding rising to 32,261,780. The company provides no additional financial or operational details, so the announcement has limited implications beyond confirming the corrected dilution and payables position. Investors should recognize this as a procedural update rather than a signal of broader strategic or financial change. The most important takeaway is the accurate share count and the minimal impact on the capital structure.

Announcement summary

(TSXV:DHB) Delivra Health Brands Inc. has issued a correction to its November 11, 2026 news release regarding a shares for payables settlement agreement. The company will settle approximately $90,000 of outstanding payables related to services provided to the company through the issuance of common shares. Subject to TSX Venture Exchange approval, Delivra Health will issue 999,999 common shares at a deemed price of $0.09 per share under the Debt Settlement Transaction. This corrects a typographical error in the prior release, which incorrectly stated that 9,999,999 shares would be issued. Immediately following the Debt Settlement Transaction, Delivra Health will have 32,261,780 shares issued and outstanding on a non-diluted basis. All other aspects of the prior release remain effective. The Debt Settlement Transaction is subject to TSX Venture Exchange approval. The shares to be issued are in satisfaction of payables for services provided to the company. The deemed price per share for the settlement is $0.09. The total number of shares to be issued is 999,999. The aggregate amount of payables being settled is approximately $90,000. The company previously reported an incorrect number of shares to be issued due to a typographical error. The corrected number of shares to be issued is 999,999. The total shares outstanding after the transaction will be 32,261,780 on a non-diluted basis. The company is listed on the TSX Venture Exchange under the ticker DHB and on the OTCQB under the ticker DHBUF.

Disagree with this article?